Reply to the Letter to the Editor re: Antibiotic Use in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Multicenter Retrospective Cohort Study - Report - MDSpire

Reply to the Letter to the Editor re: Antibiotic Use in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Multicenter Retrospective Cohort Study

  • By

  • Arnav Agarwal

  • Amol Verma

  • June 15, 2026

  • 0 min

Share

Response to Editorial Correspondence on Antibiotic Administration During AECOPD

Overview

This report addresses the complexities of antibiotic use during acute exacerbations of chronic obstructive pulmonary disease (AECOPD). It emphasizes the need for targeted antibiotic therapy based on clinical indicators rather than routine administration, as broader prescribing does not correlate with improved patient outcomes.

Background

Antibiotic therapy in AECOPD remains a contentious issue due to the heterogeneous nature of exacerbations, which can be caused by various factors including bacterial infections. Understanding when to prescribe antibiotics is crucial, as inappropriate use can lead to adverse outcomes and antibiotic resistance. Recent guidelines advocate for targeted use based on specific clinical criteria.

Data Highlights

No numerical data presented in the source material.

Key Findings

['Non-pneumonic AECOPD exacerbations are biologically heterogeneous, complicating antibiotic prescribing.', 'Greater physician-level prescribing of antibiotics did not correlate with better outcomes in hospitalized patients.', 'Clinical features such as sputum purulence are important for determining the need for antibiotics.', 'Biomarkers like C-reactive protein were rarely measured, limiting subgroup analyses.', 'Future studies are needed to identify hospitalized patients with non-pneumonic AECOPD who would benefit most from antibiotics.']

Clinical Implications

Clinicians should focus on targeted antibiotic therapy for patients with AECOPD, guided by specific clinical symptoms and features. The use of biomarkers may enhance decision-making, but current practices show limited incorporation of such measures in inpatient settings.

Conclusion

The findings reinforce the importance of a tailored approach to antibiotic use in AECOPD, emphasizing the need for further research to optimize treatment strategies for this patient population.

Related Resources & Content

  1. Open Forum Infectious Diseases, 2021 -- An Observational Cohort Study of Targeted Antibiotic Treatments of Cystic Fibrosis Exacerbations
  2. Infection, 2015 -- Factors Influencing Bacteriological Outcomes During Exacerbations of Chronic Obstructive Pulmonary Disease
  3. Open Forum Infectious Diseases, 2021 -- Response to the Commentary by Mitaka et al
  4. Global Initiative for Chronic Obstructive Lung Disease, 2026 -- GOLD Report 2026
  5. ScienceDirect, 2024 -- Procalcitonin-guided use of antibiotic in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized clinical trial
  6. Drugs - Real World Outcomes — Evaluating the Risk of Severe COPD Exacerbations and Long-Acting Bronchodilator Therapies: A Comparison of Three Observational Data Analysis Approaches
  7. Global Initiative for Chronic Obstructive Lung Disease
  8. Procalcitonin-guided use of antibiotic in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized clinical trial - ScienceDirect

Original Source(s)

Related Content